I pray you and your loved ones are staying safe as this coronavirus continues its deadly march.
I have good news for you. I have bad news for you. And I have some investable ideas, so you can protect your wealth and potentially grow it in these dark times.
Let’s start with the bad news. Coronavirus deaths in the U.S. continue to double every three days.
Here’s a chart, courtesy of Britain’s Financial Times …
More bad news: Even if things are done “perfectly”, the White House predicts the U.S will still see 100,000 to 200,000 deaths from the COVID-19 virus.
That should sober anybody up. This is no hoax, no joke. COVID-19 is spreading around the world. Now, the world is fighting back against the virus.
Forget World War 3. This is “World War V”.
The good news is that medical companies are responding with a furious frenzy of research. In fact, I just told my Supercycle Investor subscribers about a company that has invented a COVID-19 test that just takes five minutes, rather than a few days.
That REALLY should help contain the spread of the virus.
Also, Johnson & Johnson (NYSE: JNJ) said on Monday that it has a new experimental vaccine to fight the coronavirus. Human testing will begin by September and it could be available for emergency use authorization in early 2021.
Last week, I told you about three stocks at the front lines of the war against the invisible enemy. All are moving higher. Now, let me tell you about three more stocks that might help win our war against this virus …
Altimmune Inc. (Nasdaq: ALT)
This clinical-stage biopharmaceutical firm just announced advancement of a single-dose, intranasal vaccine to protect against COVID-19.
Says Vipin K. Garg, Ph.D., President and CEO: “We believe that our intranasal vaccine technology is especially well suited to provide systemic protection against respiratory infections that affect the upper and lower airways and can therefore be a useful tool in preventing further spread of COVID-19.”
The new vaccine is based on the same technology as NasoVAX, the company’s influenza vaccine candidate.
Clinical testing could begin by August.
iBio, Inc. (NYSE: IBIO)
iBio and Beijing CC-Pharming Ltd. are expediting a new COVID-19 vaccine, leveraging past work on Ebola and Dengue fever … as well as the MERS coronavirus.
If successful, the research will deliver candidates that can be quickly produced at iBio’s FastPharmingfacility in Bryan, Texas. The factory is equipped with automated hydroponics and uses a relative of the tobacco plant as the “bioreactor.”
iBio’s factory is part of the “Blue Angel” initiative for rapid delivery of countermeasures in a pandemic.
Novavax Inc. (NASDAQ: NVAX)
This company’s experience with MERS and SARS “allowed us to mobilize quickly against COVID-19 and successfully complete the critical preliminary steps to engineer viable vaccine candidates,” said Novavax President and CEO Stanley Erck.
Novavax knows the terrain, having developed programs for Zika, Ebola, swine flu and the avian bird flu.
The company develops candidates using its proprietary “recombinant protein nanoparticle” strategy. It is already evaluating them in animal models — a critical step toward testing in humans.
It aims to start human trials by the end of spring.
All three stocks have enjoyed big rallies in the past six weeks. Altimmune is up 72%. Novavax is up more than 78%. And iBio is up a stunning 274%, though it is off its highs.
If World War V continues to rage around the world, these gains could be just a taste of things to come.
All the best,
Sean
